secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001437749-22-011132
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology Q1 net loss $3.4M, product revenue down 11% to $40.7M
------------------------------------------------------------------------

- GAAP net loss of $3.4M ($0.08 per share) vs net income of $16.5M ($0.41) in Q1 2021.
- Total revenue $45.7M vs $98.2M; product revenue $40.7M (down 11% YoY); royalty revenue $5.0M.
- Non-GAAP adjusted net loss $0.3M ($0.01 per share) vs adjusted net income $22.4M ($0.56) a year ago.
- Cash and marketable securities $73.9M at March 31, 2022, down from $82.1M at Dec 31, 2021.
- Upcoming milestones for neratinib trials: SUMMIT Phase II data in HER2-mutated breast cancer and biliary tract cancer H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922011132/0001437749-22-011132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922011132/pbyi20220504_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-011132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer